Multaq
Product Images NDC 54868-3086

4 FDA label images from Physicians Total Care, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Multaq (NDC 54868-3086). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Principal Display Panel (60 Tablet Bottle)

Principal Display Panel (60 Tablet Bottle)
Label for Multaq 400MG tablets from Physicians Total Care, Inc. showing the product name, strength, lot number, expiration date (01/60), product NDC 54868-3086, manufacturer Sanofi-Aventis U.S. LLC, and a barcode with numeric code 30860600000.*
FDA Label Image

Chemical Structure (Multaq 01)

Chemical Structure (Multaq 01)
Chemical structure diagram showing the molecular formula of the active ingredient in Multaq. The structure includes aromatic rings, an ethoxy group, a sulfonamide group, and diisopropylamino side chains, with a hydrochloride moiety indicated.*
FDA Label Image

Figure 1 (Multaq 02)

Figure 1 (Multaq 02)
A line graph showing cumulative incidence over 30 months comparing placebo and dronedarone groups, with the placebo group having a higher incidence. The graph includes a risk table for both groups at different time points and a reported relative risk reduction (RRR) of 24% with a p-value of 2 x 10^-8.*
FDA Label Image

Figure 2 (Multaq 03)

Figure 2 (Multaq 03)
A forest plot chart showing risk ratios (RR) with 95% confidence intervals for various characteristics including age groups, gender, presence of AF/AFL, structural heart disease, NYHA class, LVEF, beta blocking agents, ACE inhibitors or ARBs, digitalis, and calcium antagonists. The chart compares Dronedarone versus placebo effects, indicating hazard ratios and P-values for each subgroup.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.